HO1 Stock Overview Engages in the development, manufacture, and supply of diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment worldwide. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Hologic, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Hologic Historical stock prices Current Share Price US$70.00 52 Week High US$76.50 52 Week Low US$66.50 Beta 0.96 1 Month Change -6.04% 3 Month Change n/a 1 Year Change n/a 3 Year Change 3.06% 5 Year Change 50.86% Change since IPO 308.76%
Recent News & Updates Hologic, Inc. Announces New Data to Be Presented At SABCS 2024 Investigates the Potential Role of the Breast Cancer Index Test in Identifying Patients with Minimal Risk of Distant Recurrence
Hologic, Inc. to Showcase AI-Powered Breast Imaging Advancements Designed to Assess Breast Density, Enhance Workflows and Improve Cancer Detection Nov 26
Hologic, Inc. Provides Earnings Guidance for the First Quarter and Fiscal Year of 2025 Nov 05
Hologic, Inc. (NasdaqGS:HOLX) agreed to acquire Gynesonics, Inc. for $350 million. Oct 14
Hologic, Inc. to Report Q4, 2024 Results on Nov 04, 2024 Oct 04 Hologic, Inc. (NasdaqGS:HOLX) announces an Equity Buyback for $1,500 million worth of its shares. Sep 14
See more updates Hologic, Inc. Announces New Data to Be Presented At SABCS 2024 Investigates the Potential Role of the Breast Cancer Index Test in Identifying Patients with Minimal Risk of Distant Recurrence
Hologic, Inc. to Showcase AI-Powered Breast Imaging Advancements Designed to Assess Breast Density, Enhance Workflows and Improve Cancer Detection Nov 26
Hologic, Inc. Provides Earnings Guidance for the First Quarter and Fiscal Year of 2025 Nov 05
Hologic, Inc. (NasdaqGS:HOLX) agreed to acquire Gynesonics, Inc. for $350 million. Oct 14
Hologic, Inc. to Report Q4, 2024 Results on Nov 04, 2024 Oct 04 Hologic, Inc. (NasdaqGS:HOLX) announces an Equity Buyback for $1,500 million worth of its shares. Sep 14
Hologic, Inc. Provides Earnings Guidance for the Fourth Quarter of 2024
Third quarter 2024 earnings released: EPS: US$0.83 (vs US$0.16 loss in 3Q 2023) Jul 30 Hologic, Inc. (NasdaqGS:HOLX) completed the acquisition of Endomagnetics Ltd. for approximately $310 million. Jul 25
Hologic, Inc. to Report Q3, 2024 Results on Jul 29, 2024 Jul 04
Second quarter 2024 earnings released: EPS: US$0.72 (vs US$0.88 in 2Q 2023) May 03 Hologic, Inc. Reports Impairment of Intangible Assets for the Second Quarter Ended March 30, 2024
Hologic, Inc. (NasdaqGS:HOLX) signed a definitive agreement to acquire Endomagnetics Ltd. for approximately $310 million. Apr 30
Hologic, Inc. to Report Q2, 2024 Results on May 02, 2024 Apr 03
Hologic, Inc. and Biotheranostics, Inc. Announces Newly Published Study Results Reveal That Use of the Breast Cancer Index®? Test Mar 06 Hologic, Inc. Revises Earnings Guidance for the Fiscal Year 2024
First quarter 2024 earnings released: EPS: US$1.03 (vs US$0.76 in 1Q 2023) Feb 02
Hologic, Inc. Announces First and Only FDA-Cleared Digital Cytology System – Genius™ Digital Diagnostics System Feb 02
Hologic, Inc., Annual General Meeting, Mar 07, 2024 Jan 19
Namal Nawana Announces Not to Stand for Re-Election to the Board of Hologic, Inc Jan 13
Hologic, Inc. Provides Revenue Guidance for the First Quarter of 2024 Jan 08
Hologic, Inc. to Report Q1, 2024 Results on Feb 01, 2024 Jan 05
Hologic, Inc. Promotes Essex D. Mitchell to Chief Operating Officer Dec 08
Hologic, Inc. Provides Earnings Guidance for the First Quarter and Full-Year Fiscal 2024 Nov 12
Hologic, Inc. (NasdaqGS:HOLX) announces an Equity Buyback for $500 million worth of its shares. Nov 10
Hologic, Inc. to Report Q4, 2023 Results on Nov 09, 2023 Oct 06
Nanaz Mohtashami Elected to Hologic, Inc.'S Board of Directors Sep 23
Hologic, Inc. Reports Impairment Charges for the Third Quarter Ended July 1, 2023 Aug 03
New minor risk - Earnings quality Aug 01
Third quarter 2023 earnings released: US$0.16 loss per share (vs US$0.91 profit in 3Q 2022) Aug 01
Insufficient new directors Aug 01 Hologic, Inc. Revises Earnings Guidance for the Fiscal Year 2023
Hologic, Inc. to Report Q3, 2023 Results on Jul 31, 2023 Jul 06 Hologic, Inc. Announces FDA Clearance of Panther Fusion SARS-CoV-2/Flu A/B/RSV Assay May 20
Insider recently sold €182k worth of stock May 11
Second quarter 2023 earnings released: EPS: US$0.88 (vs US$1.81 in 2Q 2022) May 03
Insufficient new directors Apr 11
Hologic, Inc. Announces Approval of NovaSure V5 Global Endometrial Ablation Device in Canada and Europe Feb 16
First quarter 2023 earnings released: EPS: US$0.76 (vs US$1.97 in 1Q 2022) Feb 03
Hologic, Inc. Revises Earnings Guidance for the Fiscal Year 2023 Feb 03
Hologic, Inc. Provides Earnings Guidance for the Second Quarter of 2023 Feb 02
Hologic, Inc., Annual General Meeting, Mar 09, 2023 Jan 20
Insufficient new directors Jan 16
Hologic, Inc. Revises Revenue Results for the First Quarter of Fiscal 2023 Jan 09
Hologic, Inc. to Report Q1, 2023 Results on Feb 01, 2023 Jan 04
Insider recently sold €118k worth of stock Dec 18
Hologic, Inc. Appoints Stacey D. Stewart to the Board of Directors, Effective January 2, 2023 Dec 10
Hologic, Inc. and Biotheranostics, Inc. Announce New Data Present At SABCS 2022 Dec 07
Chairman recently sold €2.5m worth of stock Dec 03
Full year 2022 earnings released: EPS: US$5.18 (vs US$7.28 in FY 2021) Nov 17
Insufficient new directors Nov 16 Hologic, Inc. Provides Earnings Guidance for the First Quarter Ending December 31, 2022 and Year Ending September 30, 2023
Hologic, Inc. to Report Q4, 2022 Results on Oct 31, 2022 Oct 05
Hologic, Inc. (NasdaqGS:HOLX) announces an Equity Buyback for $1,000 million worth of its shares. Sep 24
Hologic, Inc. Announces Separation of Sean S. Daugherty as President, Effective September 30, 2022 Aug 31
U.S. Court of Appeals for the Federal Circuit Affirms Ruling on Minerva Surgical, Inc. and Hologic, Inc. Case Aug 12
Third quarter 2022 earnings released: EPS: US$0.91 (vs US$1.05 in 3Q 2021) Jul 29 Hologic, Inc. Provides Earnings Guidance for the Fourth Quarter Ending September 24, 2022
Hologic, Inc. Announces Two New Respiratory Assays for the Detection of COVID-19, Flu A, Flu B and RSV Jul 12 Hologic, Inc. to Report Q3, 2022 Results on Jul 27, 2022 Jul 06
Group President of International recently sold €486k worth of stock May 20
Hologic Announces FDA Approval of Aptima CMV Quant Assay for Human Cytomegalovirus May 12
Insider recently sold €153k worth of stock May 07
Second quarter 2022 earnings released: EPS: US$1.81 (vs US$2.40 in 2Q 2021) Apr 28
Hologic, Inc. Provides Earnings Guidance for the Fiscal Year 2022 Apr 28
Insufficient new directors Apr 27
Hologic, Inc. to Report Q2, 2022 Results on Apr 27, 2022 Apr 05
Insider recently sold €139k worth of stock Mar 01
First quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat Feb 04 Hologic, Inc. Provides Earnings Guidance for the Second Quarter of Fiscal 2022
Hologic, Inc. Provides Preliminary Revenue Guidance for First Fiscal Quarter Ended December 25, 2021 Jan 10
Hologic Adds Aptima SARS-CoV-2 Assay to Its Global Access Initiative in Resource-Limited Countries Jan 06
Insufficient new directors Jan 01
Insufficient new directors Jan 01
Hologic, Inc. Launches Panther Trax for High Volume Molecular Testing Dec 24
Hologic, Inc. and Biotheranostics, Inc. Presents Breast Cancer Index™ Data at SABCS 2021 Showing Net Benefit Predictive Value for Endocrine Therapy Continuation Dec 11
Insufficient new directors Dec 02 Hologic, Inc. (NasdaqGS:HOLX) completed the acquisition of Bolder Surgical, LLC from Providence Ventures, LLC.
Insider recently sold €172k worth of stock Nov 24
Hologic, Inc. to Showcase its Extensive Portfolio of Breast and Skeletal Health Products At RSNA 2021 Nov 24
Third quarter 2021 earnings released: EPS US$0.001 (vs US$0.53 in 3Q 2020) Jul 29 Shareholder Returns HO1 DE Medical Equipment DE Market 7D -3.4% -2.9% -2.6% 1Y n/a -8.5% 6.9%
See full shareholder returns
Return vs Market: Insufficient data to determine how HO1 performed against the German Market .
Price Volatility Is HO1's price volatile compared to industry and market? HO1 volatility HO1 Average Weekly Movement n/a Medical Equipment Industry Average Movement 6.6% Market Average Movement 4.8% 10% most volatile stocks in DE Market 11.2% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: HO1's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: Insufficient data to determine HO1's volatility change over the past year.
About the Company Hologic, Inc. engages in the development, manufacture, and supply of diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment worldwide. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.
Show more Hologic, Inc. Fundamentals Summary How do Hologic's earnings and revenue compare to its market cap? HO1 fundamental statistics Market cap €15.58b Earnings (TTM ) €756.66m Revenue (TTM ) €3.86b
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) HO1 income statement (TTM ) Revenue US$4.03b Cost of Revenue US$1.58b Gross Profit US$2.45b Other Expenses US$1.66b Earnings US$789.50m
Last Reported Earnings
Sep 28, 2024
Earnings per share (EPS) 3.48 Gross Margin 60.73% Net Profit Margin 19.59% Debt/Equity Ratio 49.4%
How did HO1 perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/22 23:53 End of Day Share Price 2024/12/16 00:00 Earnings 2024/09/28 Annual Earnings 2024/09/28
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Hologic, Inc. is covered by 51 analysts. 20 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution David Toung Argus Research Company Ishan Majumdar Baptista Research Charles Butler Barclays
Show 48 more analysts 
